Cerebrolysin vs MOTS-c
Side-by-side comparison of key properties, dosing, and research.
Cognitive EnhancementAnti-Aging & Longevity
CerebrolysinAnti-Aging & Longevity
MOTS-c- Summary
- Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Half-Life
- Variable for the complex; individual peptide fractions: minutes to hours
- Estimated 1–2 hours
- Admin Route
- IV, IM
- SubQ
- Research
- —
- —
- Typical Dose
- 5–10 mL
- 5–15 mg
- Frequency
- Daily for 10–20 days
- 3–5 times per week
- Key Benefits
- Promotes neurogenesis and synaptic plasticity
- Approved for stroke rehabilitation (accelerates recovery)
- Alzheimer's disease: slows progression and improves cognition
- Traumatic brain injury recovery
- Enhances memory and executive function
- Neuroprotection against oxidative stress and excitotoxicity
- Anti-amyloid and anti-tau effects
- Mood improvement and reduced anxiety
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- Side Effects
- Generally well tolerated
- Mild nausea and dizziness (IV infusion)
- Headache at initiation
- Rare: agitation (usually at very high doses)
- +2 more
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Stacks With
- —
- —